Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

(2022) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective

(2021) Masahiko Aoki et al.   Gastric Cancer

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.

(2021) Yelena Y. Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

(2020) Akitaka Makiyama et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

(2020) Zhi Peng et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers

(2020) Lillian Skidmore et al.   MOLECULAR CANCER THERAPEUTICS

The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy

(2019) Takashi Nakada et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

(2019) Naoki Takegawa et al.   INTERNATIONAL JOURNAL OF CANCER

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

(2019) Kohei Shitara et al.   LANCET ONCOLOGY

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET ONCOLOGY

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

(2016) F. Pietrantonio et al.   INTERNATIONAL JOURNAL OF CANCER

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

(2014) Eric Van Cutsem et al.   Gastric Cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET